Japan-based Santen Pharmaceuticals’s US subsidiary has invested in Clearside Biomedical as part of a research collaboration agreement into its microinjection platform for the eyes.
Clearside raised $7.9m from Santen, venture capital firms Mountain Group Capital and Hatteras Venture Partners, Georgia Research Alliance Fund and Kenan Flagler Business School Private Equity Fund.
Hatteras Venture Partners, Georgia Research Alliance and Kenan Flagler Venture Fund invested $4m to launch Clearside in January 2012.